All News

Dr Koss refused preoperative chemotherapy to avoid damaging her virulent cells, which could later be cultured and could likely provide therapeutic leads.

The authors observed that an artificial switch in cancer cells from an epithelial to a mesenchymal phenotype induced the expression of GLUT3, a protein that promotes cellular glucose uptake.

Molecular analysis is now underway to characterize subsets of patients who performed better or worse on either treatment.

Text messaging might just be the next best thing in patient engagement-at least according to the results of 1 organization's pilot program.

Even with insurers reluctant to pay, Sovaldi prescriptions have eclipsed those for all other hepatitis C pills combined in a matter of months, new data from IMS Health indicate. The promise of a real cure, with fewer nasty side effects, has prompted thousands to get treated.

A team of researchers published data Tuesday in the American Journal of Managed Care showing that prior authorization policies in Medicaid programs have significantly higher rates of severe mental illness in their prison populations.

The recommendation to the EMA came soon after Zydiga (idelalisib) was approved in the US.

Common misuse of the terms health plan and payer is making it difficult for the payer community to comply with the Health Plan Identifier (HPID) final rule, according to the Workgroup for Electronic Data Interchange (WEDI).

Given the vast technology problems many state-based exchanges experienced during the first open-enrollment period, state officials there and elsewhere remain wary of running their own websites.

Although the state and federal health insurance exchanges have most recently taken the national spotlight, attention may soon turn to private health exchanges.

The drug is to be administered right before chemotherapy or radiation, to bind to and inhibit cell division in normal cells and reduce the adverse effects of chemotherapy.

AstraZeneca has signed up Roche and Qiagen to develop two separate diagnostic tests, both using simple blood samples, to identify patients who will benefit from its lung cancer drugs.

The Obama administration and state insurance commissioners are developing new standards to oversee narrow networks as consumers begin to express concerns of limited physician choice and unexpected out-of-network costs.

New trial data confirms its use as standard therapy for CLL.

HIV-positive individuals are not usually enrolled in clinical trials, resulting in a knowledge-gap on their treatment options.

The chairmen of the House and Senate Veterans Affairs committees have reached a tentative agreement on a plan to improve veterans' healthcare.

The DNA testing firm hopes a more cooperative approach with regulators will get its business back on track.

U.S. regulators have accepted an application by Sandoz - the generics arm of Novartis - seeking approval for a copycat version of Amgen's drug Neupogen, or filgrastim, for patients with low white blood cell counts.

This week, the nation turned its attention to the split rulings of 2 state federal court of appeals.

Active implementation of cost-saving measures successfully cut down expenditure at the Norris Comprehensive Cancer Center.

Uncompensated care was supposed to be a thing of the past, but it's persisting in many states not expanding Medicaid eligibility. As an alternative, for some high-cost uninsured patients, hospitals are turning to a new option.

When weighing the risk of heart disease, how the numbers are presented to patients can make all the difference.

Following the success of robotics in prostate surgeries, the technique was expected to provide comparable results for bladder cancer surgeries as well.

The University of Buffalo is working to limit patient readmissions to hospitals and ERs via use of dashboard technology.

Opdivo (Nivolumab) recently received regulatory approval in Japan for the treatment of patients with unresectable melanoma, the first global approval for a PD-1 inhibitor.

As healthcare reform advances, experts say, dermatologists face mounting pressure to prove their mettle to insurance exchanges and accountable care organizations (ACOs).

To better align the care of beneficiaries insured under both the Medicaid and Medicare programs, CMS invited states to participate in a 3-year demonstration project. However, it seems that many beneficiaries have opted out of these care coordination programs that are offered across the country.

A federal rule requiring health insurers to spend a minimum percentage of premium dollars on medical care led to more than $332 million in rebates last year, according to HHS.

The approval is a big gain for melanoma (Yervoy) and prostate cancer (Xtandi) patients in England and Wales.

However, a point to note is that this was a small cohort study without a comparator arm.